The Biologics Prescribers Collaborative appreciates FDA’s careful consideration before approving biosimilar applicants. As of May 2019, there are 19 approved biosimilars, with additional approvals expected in the future. This index outlines several key components of biosimilars, including:
- Proprietary drug name
- Reference biologic and manufacture
- Approved indications